Cencora Set to Report Strong Earnings as Analysts Remain Positive

Coming up on January 29, Cencora, Inc. (COR) will announce its Q1 fiscal 2025 earnings, with expectations for growth and positive reports ahead.

Based in Pennsylvania, Cencora is a leading global pharmaceutical sourcing and distribution company, boasting a market cap of $45.2 billion. The firm has committed to customer-focused practices and sustainability, contributing to better access to healthcare worldwide. Analysts predict a profit of $3.50 per share for this upcoming quarter, marking a 6.7% increase from last year’s $3.28.

Just last quarter, Cencora reported earnings of $3.34 per share, which exceeded analysts’ expectations by 4.1%. Strong revenue growth, rising demand, and efficient cost management were key factors driving this performance, allowing the company to exceed earnings and revenue forecasts.

For the entire fiscal year 2025, projections show an adjusted EPS of $15.39, reflecting an 11.9% rise from the $13.76 in fiscal 2024.

Over the past 52 weeks, Cencora’s stock has increased by 10.8%. However, this lags behind the S&P 500 Index gains of 25.8% and the modest returns from the Health Care Select Sector SPDR Fund (XLV).

While Cencora’s stock growth has been steady, it has not kept pace with broader market trends. The company’s focus on innovation and strong strategic partnerships has fortified its position in the market. Just recently on November 6, COR shares increased nearly 5% after it announced Q4 earnings that surpassed expectations, with revenue jumping 14.7% year-over-year to $79.1 billion. For fiscal year 2025, the company aims for operating income growth between 5% and 6.5%, and expects revenue to grow by 7% to 9%.

Overall, analysts express a positive outlook for Cencora’s stock, which currently holds a “Strong Buy” consensus rating—an upgrade from “Moderate Buy” just three months prior. Among 15 analysts’ ratings, 11 recommend a “Strong Buy,” with 4 suggesting a “Hold.”

The average analyst price target for COR is $274.29, indicating a potential upside of 17.1% from present levels.

On the date of publication, Rashmi Kumari did not hold any positions directly or indirectly in any of the securities mentioned in this article. All information is provided for informational purposes. For further information, please refer to the Barchart Disclosure Policy here. More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.